CollPlant reports Q2 non-GAAP EPS 33c vs. 53c last year

Reports Q2 revenue $2479K vs. $10.2M last year. We made notable development progress this quarter advancing our regenerative breast implant program,” commented CEO Yehiel Tal. “This month we launched a pre-clinical trial with 200cc commercial-sized breast implants printed with Stratasys’ Origin 3D printer. This is an important milestone for us since currently there are no other commercial products that allow regeneration of soft tissues such as the breast. The previous pre-clinical results we’ve seen have been encouraging, such as tissue regeneration and vascularization, and we are looking forward to reporting more results in Q4 of 2024 and in Q1 of 2025. We also released our first ESG and Sustainability report after establishing a corporate sustainability strategy with clear targets in key areas that we believe are crucial to our stakeholders. I would like to emphasize that our overall strategy is driven by our vision to lead in regenerative medicine and improve global health with our innovative collagen technology. This first report includes tangible steps we are taking towards enabling a sustainable future.”